tetano
Editor, Senior Moderator
Engineering (Beijing). 2020 Feb 28. doi: 10.1016/j.eng.2020.02.006. [Epub ahead of print]
Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment.
Chen J[SUP]1[/SUP], Hu C[SUP]1[/SUP], Chen L[SUP]1[/SUP], Tang L[SUP]2[/SUP], Zhu Y[SUP]2[/SUP], Xu X[SUP]1[/SUP], Chen L[SUP]3[/SUP], Gao H[SUP]2[/SUP], Lu X[SUP]1[/SUP], Yu L[SUP]1[/SUP], Dai X[SUP]2[/SUP], Xiang C[SUP]1[/SUP], Li L[SUP]1,[/SUP][SUP]2[/SUP].
Author information
Abstract
H7N9 viruses quickly spread between mammalian hosts, and it carried out the risk of human-to-human transmission after outbreak in 2013. Acute respiratory distress syndrome (ARDS), lung failure, and fulminant pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was needed to treat H7N9 induced ARDS at the time. MSCs transplant into patients with H7N9 induced ARDS were conducted in a single center and open-label clinical trial. Based on the principle of voluntariness and informed consent, 44 patients with H7N9 induced ARDS were included as a control group while 17 patients with H7N9 induced ARDS were served as an experimental group with allogeneic menstrual blood-derived MSC. Notably, MSC transplantation significantly lower the mortality compared with in control group (17.6% died in MSC group vs 54.5% died in control group). Furthermore, MSC transplantation did not result in harmful effects in human body within the 5 year follow up period with 4 patients. Collectively, these results suggest that MSCs significantly improve survival rate of H7N9 induced ARDS and provide a theoretical basis for the treatment of H7N9 induced ARDS in both preclinical research and clinical studies. Because H7N9 and the corona virus disease 2019 (COVID-19) share similar complications (such as ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19.
? 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.
KEYWORDS:
Acute respiratory distress syndrome; COVID-19; Epidemic Influenza A; H7N9; Mesenchymal stem cell; Stem cell therapeutics
PMID:32292627PMCID:PMC7102606DOI:10.1016/j.eng.2020.02.006
Free PMC Article
Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment.
Chen J[SUP]1[/SUP], Hu C[SUP]1[/SUP], Chen L[SUP]1[/SUP], Tang L[SUP]2[/SUP], Zhu Y[SUP]2[/SUP], Xu X[SUP]1[/SUP], Chen L[SUP]3[/SUP], Gao H[SUP]2[/SUP], Lu X[SUP]1[/SUP], Yu L[SUP]1[/SUP], Dai X[SUP]2[/SUP], Xiang C[SUP]1[/SUP], Li L[SUP]1,[/SUP][SUP]2[/SUP].
Author information
Abstract
H7N9 viruses quickly spread between mammalian hosts, and it carried out the risk of human-to-human transmission after outbreak in 2013. Acute respiratory distress syndrome (ARDS), lung failure, and fulminant pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was needed to treat H7N9 induced ARDS at the time. MSCs transplant into patients with H7N9 induced ARDS were conducted in a single center and open-label clinical trial. Based on the principle of voluntariness and informed consent, 44 patients with H7N9 induced ARDS were included as a control group while 17 patients with H7N9 induced ARDS were served as an experimental group with allogeneic menstrual blood-derived MSC. Notably, MSC transplantation significantly lower the mortality compared with in control group (17.6% died in MSC group vs 54.5% died in control group). Furthermore, MSC transplantation did not result in harmful effects in human body within the 5 year follow up period with 4 patients. Collectively, these results suggest that MSCs significantly improve survival rate of H7N9 induced ARDS and provide a theoretical basis for the treatment of H7N9 induced ARDS in both preclinical research and clinical studies. Because H7N9 and the corona virus disease 2019 (COVID-19) share similar complications (such as ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19.
? 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.
KEYWORDS:
Acute respiratory distress syndrome; COVID-19; Epidemic Influenza A; H7N9; Mesenchymal stem cell; Stem cell therapeutics
PMID:32292627PMCID:PMC7102606DOI:10.1016/j.eng.2020.02.006
Free PMC Article